Merck & Co., Inc.
149.54
-2.33% (최근 종가 153.10)
Company profile — from Yahoo Finance
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Company information as provided by Yahoo Finance. Check the official filings before relying on it.
Market Cap
3,812억 달러
PER
123.6배
Trailing 12 months
Forward P/E
16.2배
Forward estimates
ROE
7.0%
Return on equity
Dividend Yield
2.2%
Beta
0.21
Volatility vs market
52주 범위에서 91% 지점입니다. 100%에 가까울수록 1년 최고가 부근입니다.
Source: Yahoo Finance
Average analyst price target
범위 $105.00 ~ $186.00 · 애널리스트 26명 · 종합의견 매수 · 출처 Yahoo Finance
Analyst rating breakdown (2026-08-01)
월가는 이 종목을 뚜렷한 매수 우위로 보고 있습니다. (매수 25 · 관망 11 · 매도 0)
Revenue trend
650억 달러
2022–2025 회계연도 · 축 단위는 달러입니다.
Net income trend
183억 달러
2022–2025 회계연도 · 축 단위는 달러입니다.
| Year | Revenue | Operating Income | Net Income | Operating Cash Flow | Net Margin |
|---|---|---|---|---|---|
| 2025 | 650억 달러 | 221억 달러 | 183억 달러 | 165억 달러 | 28.1% |
| 2024 | 642억 달러 | 202억 달러 | 171억 달러 | 215억 달러 | 26.7% |
| 2023 | 601억 달러 | 30억 달러 | 4억 달러 | 130억 달러 | 0.6% |
| 2022 | 593억 달러 | 183억 달러 | 145억 달러 | 191억 달러 | 24.5% |
회계연도 기준 실적입니다(달력 연도와 다를 수 있습니다). 출처: Yahoo Finance. 값이 없는 항목은 채우지 않고 "-"로 둡니다.
SeekingAlpha · 08. 26.
ChartMill · 08. 26.
ChartMill · 08. 26.
Prices, key stats, price targets, annual financials, filings and news above come straight from Yahoo Finance · Finnhub · SEC EDGAR, so they look the same for any US-listed ticker.
Support & resistance shows above whenever my TradingView indicator is sending alerts for the ticker. No alert is set up for this one yet, so there are no levels.
Option levels · MJM Score · REAL_BUY signals come through a Google Sheet and are still limited to the fixed watchlist. We leave them out rather than guess.